Roemer K, Burgess H, Sands, KE, Hodgin R. Oral vancomycin versus fidaxomicin for Clostridiodes difficile: A comparative retrospective evaluation across a large, multi-center healthcare system.

“In the base case, FID-VAN had only a 0.4% likelihood of being cost effective versus VAN-FID at a £20,000 ($25,494) per QALY gained threshold, and a 2.3% likelihood at a £30,000 ($38,241) per ...